Omega-3 Dietary Supplements in Schizophrenia

NACompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

September 30, 2015

Study Completion Date

September 30, 2015

Conditions
SchizophreniaSchizophreniform DisorderSchizoaffective DisorderBipolar DisorderPsychosis NOS
Interventions
DRUG

Risperidone

The dosage for risperidone will be 1 mg to 6 mg per day. The dose of the risperidone will be based on the participant's clinical improvement and side effects.

DRUG

Omega-3 capsules

The total daily dose for omega-3 subjects will be 740 mg of eicosapentanoic acid (EPA)and 400 mg of docosahexaenoic acid(DHA). This dose will start on day 1 and stay the same dose until study completion.

DRUG

Placebo

The total daily dose for subjects assigned to placebo will be 2000 mg. This dose will start on day 1 and stay the same dose until study completion.

Trial Locations (1)

11040

The Zucker Hillside Hospital, Glen Oaks

All Listed Sponsors
collaborator

National Institute of Mental Health (NIMH)

NIH

collaborator

National Alliance for Research on Schizophrenia and Depression

OTHER

lead

Delbert Robinson

OTHER

NCT01786239 - Omega-3 Dietary Supplements in Schizophrenia | Biotech Hunter | Biotech Hunter